Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Short Interest Update

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was the recipient of a significant growth in short interest in February. As of February 28th, there was short interest totalling 2,570,000 shares, a growth of 16.8% from the February 13th total of 2,200,000 shares. Currently, 2.5% of the company’s stock are sold short. Based on an average daily trading volume, of 916,800 shares, the days-to-cover ratio is presently 2.8 days.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Robert W. Baird dropped their price target on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 5th. Canaccord Genuity Group lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 17th. Truist Financial lowered their target price on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th. BMO Capital Markets reduced their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating for the company in a report on Tuesday, February 4th. Finally, Canaccord Genuity Group initiated coverage on Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price for the company. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $973.13.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Pinney & Scofield Inc. bought a new stake in Regeneron Pharmaceuticals during the fourth quarter worth approximately $25,000. FSA Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals during the 3rd quarter valued at $26,000. OFI Invest Asset Management acquired a new position in Regeneron Pharmaceuticals during the 4th quarter valued at $28,000. Rakuten Securities Inc. boosted its holdings in Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 15 shares during the period. Finally, Avalon Trust Co acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter worth about $36,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Down 1.4 %

NASDAQ:REGN opened at $662.62 on Friday. The business’s fifty day moving average price is $690.20 and its 200 day moving average price is $821.82. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $72.44 billion, a price-to-earnings ratio of 17.31, a PEG ratio of 2.34 and a beta of 0.27. Regeneron Pharmaceuticals has a 1-year low of $642.00 and a 1-year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same period last year, the company earned $11.86 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up 10.3% compared to the same quarter last year. On average, sell-side analysts forecast that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.53%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.